Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Risks To Business A third risk to consider would be regarding the partnership with AstraZeneca that had been done to advance siRNA drug candidate for the treatment of patients with cardiovascular, renal, metabolic and respiratory diseases. Thus far, Silence Therapeutics was able to receive $10 million from the collaboration agreement because of the nomination of one candidate. The ability to obtain additional milestone payments is going to depend upon whether other candidates are ultimately nominated. There ...